NASDAQ:FLNA Cassava Sciences Q3 2026 Earnings Results & Report $0.50 +0.00 (+0.75%) As of 02:50 PM Eastern Cassava Sciences reported Q3 2026 earnings on November 5, 2026. The company reported EPS of -$0.22. Research:ProfileEarnings HistoryForecast Earnings Announcement Details QuarterQ3 2026Report DateNovember 5, 2026TimeBefore Market OpensConference Call8:00 AM ET Cassava Sciences EPS ResultsActual EPS-$0.22Consensus EPS N/ABeat/MissN/AOne Year Ago EPSN/AEPS Beat Rate6 of last 8 quartersCassava Sciences Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/AConference Call ResourcesPress Release (8-K)Quarterly Report (10-Q)Earnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(8-K)Quarterly report(10-Q) Cassava Sciences Q3 2026 Earnings FAQ Did Cassava Sciences beat earnings estimates for Q3 2026? Cassava Sciences (NASDAQ:FLNA) reported earnings of -$0.22 per share for Q3 2026. The report was announced on Thursday, November 5, 2026. Cassava Sciences Earnings HeadlinesFilana Therapeutics to Participate in the 2026 Maxim Growth SummitOctober 9, 2026 | globenewswire.comPositive FDA Decision Propels Rebranded Filana Therapeutics Epilepsy Research ForwardSeptember 22, 2026 | benzinga.comI'm handing you this one freeElon Musk doesn't own the chip powering every Tesla, every Starlink dish, and every AI satellite he builds. He licenses it from one overlooked company. That supplier just got a major catalyst. Musk filed to launch 1,000,000 satellites, a move analyst Dylan believes could drive a 100X bigger bill for this chipmaker starting December 8th.November 10 at 1:00 AM | Behind the Markets (Ad)Filana Therapeutics Announces FDA Lift of Clinical Hold on Simufilam, Enabling Phase 2a Study in TSC-Related EpilepsySeptember 22, 2026 | globenewswire.comFilana Therapeutics, Inc.(NasdaqCM:FLNA) dropped from S&P Global BMI IndexSeptember 20, 2026 | marketscreener.comMDid Filana Therapeutics, Inc. Insiders Breach their Fiduciary Duties to Shareholders?August 12, 2026 | prnewswire.comSee More Cassava Sciences Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Cassava Sciences? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Cassava Sciences and other key companies, straight to your email. Email Address About Cassava SciencesCassava Sciences (NASDAQ:FLNA) is a clinical-stage biopharmaceutical company focused on developing treatments and diagnostic technologies for neurodegenerative diseases, particularly Alzheimer’s disease. The company’s research platform centers on filamin A, a scaffolding protein that Cassava believes may contribute to disease-related signaling when altered. Cassava’s primary drug candidate has been simufilam, an investigational oral therapy designed to modify altered filamin A and potentially address biological processes associated with Alzheimer’s disease. The company has also developed SavaDx, an investigational blood-based diagnostic intended to detect biological changes associated with Alzheimer’s disease. Neither product has been established as an approved commercial treatment or diagnostic. Founded in 1998 as Pain Therapeutics, Cassava Sciences is headquartered in Austin, Texas. Remi Barbier, the company’s founder, has served as its chief executive officer. Cassava Sciences trades under the Nasdaq symbol SAVA; FLNA is not the company’s listed ticker symbol.View Cassava Sciences ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles DraftKings Just Lost 20%—And Its Biggest Gamble Is Still AheadBarrick's Earnings Beat Could Be Overshadowed by an Even Bigger OpportunityAxon vs. Motorola: Which Public Safety Stock Has More Upside After Q3 Earnings?Oklo Changes the Narrative: Does a Nuclear Stock Price Explosion Come Next?Wall Street May Be Making a Big Mistake With monday.com StockCloudflare's 20% Sell-Off May Have Created an Opening for InvestorsMarketBeat Week in Review – 11/2 - 11/6 Upcoming Earnings Brookfield (11/12/2026)NU (11/12/2026)Applied Materials (11/12/2026)Cisco Systems (11/12/2026)Mizuho Financial Group (11/13/2026)Mitsubishi UFJ Financial Group (11/13/2026)Sumitomo Mitsui Financial Group (11/13/2026)Home Depot (11/17/2026)Walt Disney (11/17/2026)NVIDIA (11/17/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
